First quarter 2020 financing reached $13.8bn, mostly from follow-on public offerings, which garnered $5.3bn or 38% of the Q1 total (see Exhibit 1). The FOPO group included 17 $100m-plus transactions (with an average deal value of $123m) capped off by large public offerings by life sciences contract research organization (CRO) Catalent Inc. (drug delivery and manufacturing of pharmaceuticals, biologics, and consumer health products) [See Deal] and messenger RNA (mRNA) therapies and vaccines developer Moderna Inc. [See Deal], which respectively netted $493.9m and $478.75m. Catalent expects to spend approximately $330m of these proceeds on its concurrent $315m acquisition of cell therapy contract development and manufacturing organization (CDMO) MaSTherCell Global Inc. [See Deal], and with the rest plans to pay down $100m in debt. Shortly following its FOPO, Catalent also raised €825m ($903.4m) in a separate debt financing [See Deal].
By Deal Type
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?